Market research
CYAD Celyad SA
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 8.52
- Dividend yield
- 0.0%
- Beta
- 1.69
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US1512052002
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 8.52
- Dividend yield
- 0.0%
- Beta
- 1.69
About
About Celyad SA
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CYAD discussion.
5 years, 4 months ago
Celyad Oncology SA is currently in a long term downtrend where the price is trading 32.1% below its 200 day moving average.
From a valuation standpoint, the stock is 1137.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16572.9.
Celyad Oncology SA's total revenue sank by 58.3% to $2K since the same quarter in the previous year.
Its net income has increased by 34.5% to $-8M since the same quarter in the previous year.
Finally, its free cash flow grew by 2.0% to $-7M since the same quarter in the previous year.
Based on the above factors, Celyad Oncology SA gets an overall score of 2/5.